Enprostil

Enprostil

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A02BB02 ( WHO )
Identifiers
IUPAC name methyl 7-[(1S,2S,3S)-3-hydroxy-2-[(3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate
CAS Number	73121-56-9  Y
PubChem CID	5311225
ChemSpider	4470744
UNII	J4IP5Z9DAU
KEGG	D01891  Y
Chemical and physical data
Formula	C23H28O6
Molar mass	400.471 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC(=O)CCC=C=CC[C@@H]1[C@H]([C@@H](CC1=O)O)/C=C/[C@H](COc2ccccc2)O
InChI InChI=1S/C23H28O6/c1-28-23(27)12-8-3-2-7-11-19-20(22(26)15-21(19)25)14-13-17(24)16-29-18-9-5-4-6-10-18/h3-7,9-10,13-14,17,19-20,22,24,26H,8,11-12,15-16H2,1H3/b14-13+/t2?,17-,19-,20-,22-/m1/s1 Key:PTOJVMZPWPAXER-VFJVYMGBSA-N
(verify)

Enprostil is a synthetic prostaglandin designed to resemble dinoprostone. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion. ^[1] It is an analog of prostaglandin E2 but unlike this prostaglandin, which binds to and activates all four cellular receptors viz., EP1, EP2, EP3, and EP4 receptors, enprostil is a more selective receptor agonist in that it binds to and activates primarily the EP3 receptor. ^[2] Consequently, enprostil is expected to have a narrower range of actions that may avoid some of the unwanted side-effects and toxicities of prostaglandin E2. A prospective multicenter randomized controlled trial conducted in Japan found combining enprostil with cimetidine was more effective than cimetidine alone in treating gastric ulcer. ^[3]

See also

• Prostaglandin receptors
• EP3 and peptic ulcer

References

1. Roszkowski AP, Garay GL, Baker S, Schuler M, Carter H (November 1986). "Gastric antisecretory and antiulcer properties of enprostil, (+/-)-11 alpha, 15 alpha-dihydroxy-16-phenoxy-17,18,19,20-tetranor-9-oxoprosta- 4,5,13(t)-trienoic acid methyl ester". The Journal of Pharmacology and Experimental Therapeutics. 239 (2): 382–389. PMID   3095537.
2. Moreno JJ (February 2017). "Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis". European Journal of Pharmacology. 796: 7–19. doi:10.1016/j.ejphar.2016.12.004. PMID   27940058. S2CID   1513449.
3. Murata H, Kawano S, Tsuji S, Tsujii M, Hori M, Kamada T, et al. (2005). "Combination of enprostil and cimetidine is more effective than cimetidine alone in treating gastric ulcer: prospective multicenter randomized controlled trial". Hepato-Gastroenterology. 52 (66): 1925–1929. PMID   16334808.

Further reading

• Toshina K, Hirata I, Maemura K, Sasaki S, Murano M, Nitta M, et al. (December 2000). "Enprostil, a prostaglandin-E(2) analogue, inhibits interleukin-8 production of human colonic epithelial cell lines". Scandinavian Journal of Immunology. 52 (6): 570–575. doi:10.1046/j.1365-3083.2000.00815.x. PMID   11119262.
• Tari A, Hamada M, Kamiyasu T, Sumii K, Haruma K, Inoue M, et al. (August 1997). "Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients". Digestive Diseases and Sciences. 42 (8): 1741–1746. doi:10.1023/A:1018825902055. PMID   9286243. S2CID   25069361.
• Ching CK, Lam SK (October 1995). "A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease". Journal of Gastroenterology. 30 (5): 607–614. doi:10.1007/BF02367786. PMID   8574332. S2CID   6288648.